Sonrotoclax

Sonrotoclax
Clinical data
Pronunciation	/sɒnˈroʊtəklæks/; son-ROH-tə-klaks
Trade names	Beqalzi
AHFS/Drugs.com	Monograph
MedlinePlus	a626069
License data	US DailyMed: Sonrotoclax;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3-nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin-1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide;
CAS Number	2383086-06-2;
PubChem CID	149553242;
DrugBank	DB18753;
ChemSpider	129309008;
UNII	30R67U9KYS;
KEGG	D12883;
ChEMBL	ChEMBL5314951;
Chemical and physical data
Formula	C49H59N7O7S
Molar mass	890.11 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC=CC=C1[C@@H]2CCCN2C3CC4(C3)CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NCC7CCC(CC7)(C)O)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9;
	InChI InChI=1S/C49H59N7O7S/c1-32(2)39-7-4-5-8-40(39)43-9-6-22-55(43)36-28-49(29-36)19-23-54(24-20-49)35-10-12-41(45(26-35)63-37-25-34-16-21-50-46(34)52-31-37)47(57)53-64(61,62)38-11-13-42(44(27-38)56(59)60)51-30-33-14-17-48(3,58)18-15-33/h4-5,7-8,10-13,16,21,25-27,31-33,36,43,51,58H,6,9,14-15,17-20,22-24,28-30H2,1-3H3,(H,50,52)(H,53,57)/t33?,43-,48?/m0/s1; Key:ZQTKOYMWCCSKON-HCWAPQBJSA-N;

Sonrotoclax, sold under the brand name Beqalzi, is an anti-cancer medication used for the treatment of mantle cell lymphoma.^[1] It is a BCL-2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.^[2]

Medical uses

Sonrotoclax is indicated for the treatment of adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.^[3]

Contraindications

Sonrotoclax is contraindicated with strong CYP3A inhibitors at initiation and ramp-up phase due to potential increased risk of Tumor lysis syndrome.^[3]

Society and culture

Legal status

Sonrotoclax was approved for medical use in the United States in May 2026.^[3] Sonrotoclax is also approved in China for mantle cell lymphoma, along with CLL/SLL.^[3]

Sonrotoclax also has a fast track designation by the FDA for Waldenström macroglobulinemia. It additionally has an orphan drug designation by the FDA for Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.^[3]

Names

Sonrotoclax is the international nonproprietary name.^[4]

Sonrotoclax is sold under the brand name Beqalzi.^[3]

References

1 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220711Orig1s000lbl.pdf
↑ Tomkins O, D'Sa S (2024). "Review of BCL2 inhibitors for the treatment of Waldenström's macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma". Frontiers in Oncology. 14 1490202. doi:10.3389/fonc.2024.1490202. PMC 11570586. PMID 39558954.
1 2 3 4 5 6 "BeOne Medicines' Beqalzi (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma" (Press release). Beone Medicines. 13 May 2026. Retrieved 23 May 2026 – via Business Wire.
↑ World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information. 37 (3). hdl:10665/373341.

[Beqalzi_FDA_label-1] 1 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220711Orig1s000lbl.pdf

[Tomkins_2024-2] Tomkins O, D'Sa S (2024). "Review of BCL2 inhibitors for the treatment of Waldenström's macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma". Frontiers in Oncology. 14 1490202. doi:10.3389/fonc.2024.1490202. PMC 11570586. PMID 39558954.

[Beone_Medicines_PR-3] 1 2 3 4 5 6 "BeOne Medicines' Beqalzi (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma" (Press release). Beone Medicines. 13 May 2026. Retrieved 23 May 2026 – via Business Wire.

[4] World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information. 37 (3). hdl:10665/373341.

[1]

[2]

[3]

[4]